{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:52:26Z","timestamp":1761663146437,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.ijantimicag.2012.12.017","type":"journal-article","created":{"date-parts":[[2013,2,24]],"date-time":"2013-02-24T15:48:09Z","timestamp":1361720889000},"page":"372-378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effectiveness and safety of daptomycin in complicated skin and soft-tissue infections and bacteraemia in clinical practice: Results of a large non-interventional study"],"prefix":"10.1016","volume":"41","author":[{"given":"Armando","family":"Gonzalez-Ruiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Beiras-Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Lehmkuhl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal M.","family":"Dohmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juergen","family":"Loeffler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo L.","family":"Chaves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2012.12.017_bib0005","first-page":"ii37","article-title":"Complicated infections of skin and skin structures: when the infection is more than skin deep","volume":"53","author":"DiNubile","year":"2004","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2012.12.017_bib0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1469-0691.2008.01922.x","article-title":"Treatment challenges in the management of complicated skin and soft-tissue infections","volume":"14","author":"Eisenstein","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2012.12.017_bib0015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1471-2334-10-151","article-title":"Skin and soft tissue infections in hospitalized and critically ill patients: a nationwide population-based study","volume":"10","author":"Shen","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.12.017_bib0020","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1086\/497143","article-title":"Infectious Diseases Society of America Practice guidelines for the diagnosis and management of skin and soft-tissue infections","volume":"41","author":"Stevens","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2012.12.017_bib0025","doi-asserted-by":"crossref","first-page":"s3","DOI":"10.1089\/sur.2008.066.supp","article-title":"Complicated skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus: epidemiology, risk factors, and presentation","volume":"9","author":"Dryden","year":"2008","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.ijantimicag.2012.12.017_bib0030","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1086\/526444","article-title":"Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections","volume":"29","author":"Edelsberg","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2012.12.017_bib0035","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1592\/phco.27.12.1611","article-title":"Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes","volume":"27","author":"Davis","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2012.12.017_bib0040","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1086\/420818","article-title":"The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections","volume":"38","author":"Arbeit","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.12.017_bib0045","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijantimicag.2011.09.011","article-title":"Retrospective case\u2013control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy","volume":"39","author":"Falcone","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2012.12.017_bib0050","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijantimicag.2011.08.007","article-title":"Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections","volume":"39","author":"Quist","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2012.12.017_bib0055","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 4","key":"10.1016\/j.ijantimicag.2012.12.017_bib0060","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1086\/598189","article-title":"Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies","volume":"48","author":"Naber","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.12.017_bib0065","unstructured":"European Antimicrobial Resistance Surveillance System. EARSS Annual Report 2008. European Centre for Disease Prevention and Control; 2008. http:\/\/ecdc.europa.eu\/en\/activities\/surveillance\/EARS-Net\/publications\/Pages\/documents.aspx [accessed 07.02.13]."},{"key":"10.1016\/j.ijantimicag.2012.12.017_bib0070","unstructured":"Novartis Europharm Ltd. Cubicin\u00ae (daptomycin) summary of product characteristics. 2012"},{"key":"10.1016\/j.ijantimicag.2012.12.017_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2010.03.020","article-title":"Patients included in randomised controlled trials do not represent those seen in clinical practice: focus on antimicrobial agents","volume":"36","author":"Falagas","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2012.12.017_bib0080","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/jac\/dkq528","article-title":"Clinical experience with daptomycin in Europe: the first 2.5 years","volume":"66","author":"Gonzalez-Ruiz","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2012.12.017_bib0085","first-page":"233","article-title":"Consensus document on treatment of infections in diabetic foot","volume":"24","author":"Blanes","year":"2011","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.ijantimicag.2012.12.017_bib0090","unstructured":"Levine DP, Durante-Mangoni E, Utili R, Lamp KC, Yoon M, Chaves RL. Multinational clinical experience with high dose daptomycin for the treatment of native valve endocarditis. In: 11th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections; 24\u201326 July 2011; Cairns, Australia. Darlinghurst, Australia: Australasian Society for HIV Medicine Inc. Poster 121."},{"key":"10.1016\/j.ijantimicag.2012.12.017_bib0095","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.12.017_bib0100","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijantimicag.2010.10.030","article-title":"Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits?","volume":"37","author":"Gould","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2012.12.017_bib0105","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1592\/phco.29.7.792","article-title":"Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients","volume":"29","author":"Gallagher","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2012.12.017_bib0110","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2012.12.017_bib0115","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s100960000299","article-title":"Glycopeptide resistance in coagulase-negative staphylococci","volume":"19","author":"Biavasco","year":"2000","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2012.12.017_bib0120","first-page":"ii65","article-title":"Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001\u201306","volume":"62","author":"Hope","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2012.12.017_bib0125","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/jac\/dkq087","article-title":"A potential role for daptomycin in enterococcal infections: what is the evidence?","volume":"65","author":"Canton","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2012.12.017_bib0130","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1179\/joc.2009.21.5.500","article-title":"Update of the in vitro activity of daptomycin tested against 17,193 Gram-positive bacteria isolated from European medical centers (2005\u20132007)","volume":"21","author":"Sader","year":"2009","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2012.12.017_bib0135","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1179\/joc.2011.23.4.200","article-title":"Antimicrobial activity of daptomycin tested against Gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003\u20132009)","volume":"23","author":"Sader","year":"2011","journal-title":"J Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857913000289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857913000289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:31:52Z","timestamp":1760376712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857913000289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0924857913000289"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2012.12.017","relation":{},"ISSN":["0924-8579"],"issn-type":[{"type":"print","value":"0924-8579"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of daptomycin in complicated skin and soft-tissue infections and bacteraemia in clinical practice: Results of a large non-interventional study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2012.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}